Yogesh Purushotham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yogesh Purushotham has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Tamar Sofer
Beth Israel Deaconess Medical Center
2 shared publications - Aarti Asnani
Beth Israel Deaconess Medical Center , Boston, Massachusetts
1 shared publication - Abraham L. Bayer
Department of Immunology, School of Medicine (R.E., Z.R., C.K., S.S., A.L.B., P.A.), Tufts University, Boston, MA
1 shared publication - Abul Ariza Manzano
CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (A.L.B., A. Ariza, M.U., J.M.N.-P., C.C., Y.P., S.A., A.N.R.D., J.B., L.F., J.N.U., C.W.H., M.L., R.G., A. Asnani)
1 shared publication Andrea Nathalie Rosas Diaz
CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (A.L.B., A. Ariza, M.U., J.M.N.-P., C.C., Y.P., S.A., A.N.R.D., J.B., L.F., J.N.U., C.W.H., M.L., R.G., A. Asnani)
1 shared publicationBeisha Tang
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
1 shared publication
Latest Publications
- 27 August 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies
BACKGROUND: Anthracyclines such as doxorubicin are well recognized to induce dose-dependent cardiotoxicity. However, traditional imaging and blood biomarkers of myocardial injury are inadequate for early risk stratification. We aimed to discover plasma proteins that correlate with the subsequent development of anthracycline-induced systolic dysfunction in patients, with validation studies in preclinical models. METHODS: We used an aptamer-based proteomics platform to measure over 7000 proteins in the plasma obtained at baseline (before anthracycline chemotherapy) in a prospectively enrolled cohort of patients with hematologic malignancies (n=34). The correlation between protein levels and change in left ventricular ejection fraction was assessed. Candidate biomarkers were validated in a second patient cohort treated with anthracyclines for hematologic malignancies (n=32), as well as in a mouse model of delayed doxorubicin cardiotoxicity. RESULTS: In both discovery and validation cohorts, baseline levels of CPVL (carboxypeptidase vitellogenic-like protein) and PIGR (poly immunoglobulin receptor) measured in the plasma before anthracycline treatment correlated with a subsequent decline in left ventricular ejection fraction (PIGR: R =−0.74; P =0.0022; CPVL: R =−0.74; P =0.0022). Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin. In further support of PIGR as a biomarker representing the systemic adaptive immune response, doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction. The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival. CONCLUSIONS: Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.
- 27 August 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies
BACKGROUND: Anthracyclines such as doxorubicin are well recognized to induce dose-dependent cardiotoxicity. However, traditional imaging and blood biomarkers of myocardial injury are inadequate for early risk stratification. We aimed to discover plasma proteins that correlate with the subsequent development of anthracycline-induced systolic dysfunction in patients, with validation studies in preclinical models. METHODS: We used an aptamer-based proteomics platform to measure over 7000 proteins in the plasma obtained at baseline (before anthracycline chemotherapy) in a prospectively enrolled cohort of patients with hematologic malignancies (n=34). The correlation between protein levels and change in left ventricular ejection fraction was assessed. Candidate biomarkers were validated in a second patient cohort treated with anthracyclines for hematologic malignancies (n=32), as well as in a mouse model of delayed doxorubicin cardiotoxicity. RESULTS: In both discovery and validation cohorts, baseline levels of CPVL (carboxypeptidase vitellogenic-like protein) and PIGR (poly immunoglobulin receptor) measured in the plasma before anthracycline treatment correlated with a subsequent decline in left ventricular ejection fraction (PIGR: R =−0.74; P =0.0022; CPVL: R =−0.74; P =0.0022). Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin. In further support of PIGR as a biomarker representing the systemic adaptive immune response, doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction. The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival. CONCLUSIONS: Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.
- Open Access
Reassessing Instrument Strength in Two-Sample Mendelian Randomization Analysis
Mendelian randomization (MR) analysis is widely used to estimate causal relationships between risk factors and outcomes of interest. Two-sample MR approaches have gained increasing attention in genetic epidemiology due to the growing availability of Genome-Wide Association Study (GWAS) summary statistics from public databases. A critical step in two-sample MR is the selection of genetic variants as instrumental variables (IVs). Although genome-wide significant variants are typically preferred, the inclusion of variants with weaker association p-values is considered, as they may potentially improve power through an increased instrument number of instruments, while they may introduce weak instrument bias and attenuate effect estimates towards the null. Our simulation results show that even modest levels of pleiotropy substantially increase the variability of causal effect estimates, while the inclusion of weak IVs does not substantially affect the direction and variability of causal effect estimates in most cases. In real data analyses, we used two released versions of FinnGen GWAS summary statistics with different sample sizes as exposure GWASs to assess the influence of weak IVs. Here, the inclusion of IVs with higher exposure-association p-values resulted in weakened estimated effect sizes, particularly when the exposure GWAS sample size was small. These findings suggest that incorporating weak IVs is reasonable when the exposure GWAS sample size is large, but it poses a risk of falsely concluding null associations when the exposure GWAS sample size is small.
Open AccessReassessing Instrument Strength in Two-Sample Mendelian Randomization Analysis
Mendelian randomization (MR) analysis is widely used to estimate causal relationships between risk factors and outcomes of interest. Two-sample MR approaches have gained increasing attention in genetic epidemiology due to the growing availability of Genome-Wide Association Study (GWAS) summary statistics from public databases. A critical step in two-sample MR is the selection of genetic variants as instrumental variables (IVs). Although genome-wide significant variants are typically preferred, the inclusion of variants with weaker association p-values is considered, as they may potentially improve power through an increased instrument number of instruments, while they may introduce weak instrument bias and attenuate effect estimates towards the null. Our simulation results show that even modest levels of pleiotropy substantially increase the variability of causal effect estimates, while the inclusion of weak IVs does not substantially affect the direction and variability of causal effect estimates in most cases. In real data analyses, we used two released versions of FinnGen GWAS summary statistics with different sample sizes as exposure GWASs to assess the influence of weak IVs. Here, the inclusion of IVs with higher exposure-association p-values resulted in weakened estimated effect sizes, particularly when the exposure GWAS sample size was small. These findings suggest that incorporating weak IVs is reasonable when the exposure GWAS sample size is large, but it poses a risk of falsely concluding null associations when the exposure GWAS sample size is small.
- Open Access
- 14 March 2026
- Published by Elsevier in EBioMedicine
- Vol. 126, 106220
Shared genetic architecture between sleep traits and cardiometabolic diseases
- 14 March 2026
- Published by Elsevier in EBioMedicine
- Vol. 126, 106220
Open AccessShared genetic architecture between sleep traits and cardiometabolic diseases